We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current PYC market cap is 347.16M. The company's latest EPS is AUD -0.0061 and P/E is -14.75.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 2.46M | 3.13M | 16.04M | 15.81M |
| Operating Income | -7.1M | -7.24M | -18.7M | -14.16M | -23.36M |
| Net Income | -4.08M | -6.82M | -17.77M | -13.86M | -22.79M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 6.7M | 31.55M | 57.94M | 45.35M | 37.17M |
| Total Liabilities | 402k | 1.35M | 4.02M | 5.15M | 8.72M |
| Total Equity | 6.3M | 30.2M | 53.92M | 40.2M | 28.44M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -5.13M | -5.75M | -11.79M | -21.78M | -24.42M |
| Investing | -457k | -13.77M | -15.52M | 32.68M | -477k |
| Financing | 8.62M | 25.11M | 38.56M | -182k | 11.44M |
| Market Cap | 347.16M |
| Price to Earnings Ratio | -14.75 |
| Price to Sales Ratio | 21.43 |
| Price to Cash Ratio | 21.43 |
| Price to Book Ratio | 11.81 |
| Dividend Yield | - |
| Shares Outstanding | 3.73B |
| Average Volume (1 week) | 2.89M |
| Average Volume (1 Month) | 2.62M |
| 52 Week Change | 43.08% |
| 52 Week High | 0.115 |
| 52 Week Low | 0.05 |
| Spread (Intraday) | 0 (2.13%) |
| Company Name | PYC Therapeutics Limited |
| Address |
suite 8 perth, western australia 6053 |
| Website | https://www.pyctx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
